Publicaciones (28) Publicaciones de Teresa Ezponda Itoiz

2024

  1. KDM6A regulates immune response genes in multiple myeloma

    Blood, Vol. 144, Núm. 14, pp. 1508-1520

  2. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. Germline ERCC excision repair 6 like 2 (ERCC6L2) mutations lead to impaired erythropoiesis and reshaping of the bone marrow microenvironment

    British Journal of Haematology, Vol. 199, Núm. 5, pp. 754-764

  2. SimiC enables the inference of complex gene regulatory dynamics across cell phenotypes

    Communications Biology, Vol. 5, Núm. 1

  3. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

2019

  1. Genotyping and Sequencing

    Principles of Nutrigenetics and Nutrigenomics: Fundamentals of Individualized Nutrition (Elsevier), pp. 33-39

  2. NGS data analysis process

    Principles of Nutrigenetics and Nutrigenomics: Fundamentals of Individualized Nutrition (Elsevier), pp. 33-39

2018

  1. Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells

    Oncotarget, Vol. 9, Núm. 16, pp. 12842-12852

  2. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer

    Laboratory Investigation, Vol. 98, Núm. 12, pp. 1562-1574

2017

  1. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors

    Leukemia and Lymphoma

  2. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

    Cell Reports, Vol. 21, Núm. 3, pp. 628-640

2016

  1. H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer

    Advances in Cancer Research (Academic Press Inc.), pp. 59-95

  2. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

    Oncogene, Vol. 35, Núm. 45, pp. 5905-5915

2015

  1. Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape

    Cell Reports, Vol. 12, Núm. 8, pp. 1300-1313

2014

  1. Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation

    PLoS Genetics, Vol. 10, Núm. 9

  2. Molecular pathways: Deregulation of histone H3 lysine 27 methylation in cancer - Different paths, same destination

    Clinical Cancer Research, Vol. 20, Núm. 19, pp. 5001-5008

  3. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies

    Leukemia